ADMA Key Statistics, Chart & Performance
The current stock price of ADMA is 19.18 USD. In the past month the price increased by 25.61%. In the past year, price decreased by -4.62%.
ADMA Latest News, Press Relases and Analysis
ADMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.25B | ||
| AMGN | AMGEN INC | 15.8 | 185.98B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 111.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.15B | ||
| INSM | INSMED INC | N/A | 43.92B | ||
| NTRA | NATERA INC | N/A | 32.78B | ||
| BIIB | BIOGEN INC | 10.88 | 26.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 21.98B | ||
| INCY | INCYTE CORP | 16.27 | 20.40B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About ADMA
Company Profile
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 677 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Company Info
ADMA BIOLOGICS INC
465 State Route 17
Ramsey NEW JERSEY 07446 US
CEO: Adam S. Grossman
Employees: 677
Phone: 12014785552
ADMA BIOLOGICS INC / ADMA FAQ
What does ADMA do?
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 677 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Can you provide the latest stock price for ADMA BIOLOGICS INC?
The current stock price of ADMA is 19.18 USD. The price increased by 0.21% in the last trading session.
Does ADMA BIOLOGICS INC pay dividends?
ADMA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADMA stock?
ADMA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists ADMA stock?
ADMA stock is listed on the Nasdaq exchange.
What sector and industry does ADMA BIOLOGICS INC belong to?
ADMA BIOLOGICS INC (ADMA) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of ADMA stock?
ADMA BIOLOGICS INC (ADMA) has a market capitalization of 4.58B USD. This makes ADMA a Mid Cap stock.
ADMA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ADMA. When comparing the yearly performance of all stocks, ADMA turns out to be only a medium performer in the overall market: it outperformed 58.38% of all stocks.
ADMA Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to ADMA. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability.
ADMA Financial Highlights
Over the last trailing twelve months ADMA reported a non-GAAP Earnings per Share(EPS) of 0.54. The EPS increased by 92.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 42.87% | ||
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| Debt/Equity | 0.16 |
ADMA Forecast & Estimates
10 analysts have analysed ADMA and the average price target is 27.8 USD. This implies a price increase of 44.92% is expected in the next year compared to the current price of 19.18.
For the next year, analysts expect an EPS growth of 21.04% and a revenue growth 19.81% for ADMA